Printer Friendly

Royal DSM appoints president & CEO: Biogen names EVP of R&D, corporate development executive.

DSM Pharmaceutical Products:

Alexander Wessels has been named president and chief executive officer of the pharmaceutical ingredients and contract manufacturing organization of Royal DSM NV. He previously served as president and chief executive officer of DSM Food Specialties.

[ILLUSTRATION OMITTED]

Mr. Wessels reports to Mr. Stephan Tanda, a member of the DSM Managing Board, and will oversee the implementation of DSM's "driving focused growth" global strategy, within the pharmaceutical products business group. The strategy includes sales from high growth economies, innovation and sustainability solutions, as well as from partnerships.

Mr. Wessels has 20 years of experience working in the life sciences, nutrition and pharmaceutical industries, including four years at DSM, most recently as business group president of DSM Food Specialties. Prior to joining the company, Mr. Wessels held various management and executive positions in the food, beverage and nutrition industries at Unilever, Quest International (Unilever), ICI, and Campina.

Biogen Idec: Douglas E. Williams, Ph.D., has been named executive vice president of R&D and Steven H. Holtzman has been named executive vice president, corporate development. Dr. Williams will oversee the company's global R&D operation, including discovery research, development, clinical operations and regulatory affairs. Mr. Holtzman will oversee corporate strategy, business development, portfolio management, program leadership and the New Ventures fund. Both will report to Biogen's chief executive officer George A. Scangos, Ph.D.

Dr. Williams has more than 20 years of scientific and senior leadership experience, most recently as chief executive officer of ZymoGenetics, Inc. He also served as head of research and a member of the executive team at Immunex, where he played a significant role in the discovery and development of rheumatoid arthritis drug Enbrel.

Mr. Holtzman has more than 20 years of industry experience, most recently as founder, chairman and chief executive officer of Infinity Pharmaceuticals. Mr. Holtzman also served as chief business officer of Millennium Pharmaceuticals.

"I am delighted to welcome Doug Williams and Steve Holtzman to Biogen Idec," said Dr. Scangos. "I have known Doug and Steve for a long time and have great respect for their capabilities, accomplishments and character. Doug has repeatedly demonstrated the ability to build and lead high quality research groups and, importantly, to aggressively focus the science and transform promising research into products. Steve is one of the most thoughtful and creative business people I know and has demonstrated over the years the ability to build great organizations and create innovative collaborative structures that meet the needs of both partners. Steve and Doug represent the completion of what I believe is now an excellent management team. I look forward to working with both of them and the rest of the management team to take Biogen Idec to the next level."

Harmony Labs: Dr. Charles Gray has been appointed vice president of R&D. Dr. Gray will lead the formulation and analytical teams in the support of Harmony's Rx, OTC, Animal Health and Cosmetic market segments. Dr. Gray most recently served as executive director for product development at GlaxoSmithKline/Stiefel Laboratories. Dr. Gray also served as director of regulatory affairs at Stiefel Laboratories.

Dr. Gray succeeds John Maloney, who has been appointed vice president of Rx product and process development. Dr. Maloney has expertise in drug development, process scale-up and on-going production support. He will work to advance Harmony's Rx product development, technical and analytical services, and manufacturing offerings. Prior to joining the company four years ago, Dr. Maloney held R&D leadership positions at Taro Pharmaceuticals and Alpharma.

PharmaZell GmbH: Tracey Burr, Ph.D., has been appointed chief technology officer. Dr. Burr is responsible for R&D activities for all of the company's sites. She will report to Dr. Wolfgang Burger, managing partner of PharmaZell.

Dr. Burr has many years of experience in various R&D executive positions in the field of APIs. Dr. Burr will use her experience, technical and leadership skills to help PharmaZell further strengthen and expand its position as a CMO in the pharmaceutical industry.

"I am very pleased that we were able to get Tracey Burr on our team. Tracey's capabilities and personality as well as her experience in the pharmaceutical industry make her a great asset to the company," said Dr. Burger, managing partner of PharmaZell.

Camargo Pharmaceutical Services: Ray Dawkins, M.D., has been appointed chief medical officer. Dr. Dawkins has more than 25 years of clinical research and pharmaceutical development experience including Phase I, first-in-human and biologics. He also has expertise in Phase I-III clinical trial design, drug safety reporting, medical writing and international regulatory interaction and submissions.

"The addition of Dr. Dawkins will expand our services to include so-called bio-betters--biologics that are improved over the reference products," said Ken Phelps, president and chief executive officer of Camargo. "We use our proven knowledge of how to improve small molecule drugs to improve biologic-based drugs. In a sense, we're just living up to our brand and teaching a new dog a new trick."

Prior to joining the company, Dr. Dawkins was an executive medical director of medical affairs at Paragon Biomedical in Cary, NC. He was also the senior medical director of clinical development at Talecris Biotherapeutics in Research Triangle Park, NC. In previous positions, Dr. Dawkins was responsible for planning, implementing, leading and evaluating global projects, as well as business development and product acquisition activities.

AVI BioPharma: Effie Toshav, J.D., has been appointed senior vice president and general counsel, effective January 10th. Ms. Toshav has considerable industry-specific legal, corporate development and strategic experience. Most recently, she was a partner in the life sciences group at Wilson Sonsini Goodrich and Rosati (WSGR), where she served as outside counsel to a large number of prominent biotech companies advising management teams on a wide range of business and legal matters.

Prior to WSGR, she served as general counsel and a member of the management team at GlycoFi, where she was responsible for all legal and general corporate matters.

"Effie's talent, experience and skills add considerable breadth and depth to the management team, as does her deep expertise in the key areas of corporate development and intellectual property, as we navigate this pivotal point in the company's development," said Chris Garabedian, AVI's chief executive officer and president. "We are excited to have Effie join the team and look forward to her contribution."

PharmaNet Development Group:

Catherine Derasp, RN, has joined the company as vice president, Clinical Operations of Phase I clinics.

Ms. Derasp will oversee the management of the Company's 350 bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, Ms. Derasp will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

"We are thrilled to have Catherine join us," said Riaz Bandali, president, Early Stage Development. "Catherine's commitment to continual improvement and expertise in multi-site Phase I clinical operations, quality systems, and training brings the right combination of knowledge and experience to the PharmaNet Phase I clinical organization."

Ms. Derasp has more than 15 years of experience working for Phase I clinical research organizations. Her various leadership roles included managing global multi-site operations with specialization in operational quality and process improvement.

MPI Research: Dale M. Cooper, DVM, has been named director of Clinical Medicine. Dr. Cooper will oversee animal care for the company's three core research divisions: Drug Safety Evaluation, Discovery Services, and Bioanalytical/Analytical Services.

Dr. Cooper, a Diplomate of the American College of Laboratory Animal Medicine, brings a broad scope of veterinary clinical medical experience to MPI Research. Most recently, he was the director of Laboratory Animal Medicine, Quality, and Technical Services for North America for Harlan Laboratories. Prior to that, he was a principal research scientist with Eli Lilly. Dr. Cooper also has experience in consulting and community veterinary medicine as well as academia. He received his DVM from the University of Wisconsin, Madison and is widely published in the animal husbandry literature.

Dr." Tina Rogers, Ph.D., MBA, DABT, director of Research and executive vice president at MPI Research, remarked, "Dr. Cooper has a proven track record of ensuring the highest possible standards of animal welfare. Our company is known for its commitment to conducting studies in an ethical and humane way, and with Dr. Cooper at the helm of our animal care program, this commitment is strengthened even further."

Sartorius: Dominique Baly has been appointed president of the company's group laboratory business, responsible for cross-divisional management of marketing, sales and service. Mr. Baly reports to the chief executive officer and is a member of the group executive committee that includes six executives of Sartorius AG and the subgroup Sartorius Stedim Biotech.

Mr. Baly has more than 35 years of sales and managerial experience. He joins the company from Millipore Corp., which was acquired by Merck KGaA in 2010. From 2005 to 2008, he was president of the bioscience division. In 2009, he became chief executive officer of Accelerator Sciences LLC, a U.S. investment firm.

CTI Appoints Senior Medical Director

CTI HAS PROMOTED Bill Aronstein to senior medical director. He joins the Medical Affairs Team with years of early and late drug development experience, clinical trial experience, a breadth of medical, scientific, and historical knowledge.

[ILLUSTRATION OMITTED]

Dr. Aronstein joined CTI in November 2008 with more than 10 years of experience having held many diverse scientific and drug development positions at Proctor and Gamble, as well as a Professor of Medicine at Emory University and an attending internal medicine physician at Johns Hopkins. Prior to almost every meeting or project, Dr. Aronstein will conduct extensive background research to learn about the client and the program. He has contributed to the success of many programs, including Pharming, Osiris, Astellas, Eisai, Emergent and of course Protherics.
COPYRIGHT 2011 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:PROMOTIONS & MOVES
Publication:Contract Pharma
Date:Jan 1, 2011
Words:1630
Previous Article:Gilead ends IPF trial: GSK, Theravance begin Phase II COPD trial.
Next Article:Company showcase.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters